TipRanks
C-MER Eye Care Holdings Limited (HK:3309)
:3309
Hong Kong Market
Want to see HK:3309 full AI Analyst Report?

C-MER Eye Care Holdings Limited (3309) AI Stock Analysis

2 Followers

Top Page

HK:3309

C-MER Eye Care Holdings Limited

(3309)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - Gpt-5.6Sol)
Rating:67Neutral
Price Target:
HK$0.87
▼(-48.65% Downside)
Action:Reiterated
Date:08/06/26
The score is supported primarily by strong cash flow and a solid, moderately levered balance sheet, alongside reasonable valuation. These positives are meaningfully tempered by weak technical trends and momentum, plus a history of profit volatility that increases uncertainty.
Positive Factors
Strong cash generation
Recurring positive operating cash flow and strong free cash flow provide internal funding for clinical expansion, facility investment, and shareholder returns. The 2025 improvement in free cash flow also indicates better cash conversion, strengthening financial resilience over the next several quarters.
Negative Factors
Earnings volatility
Repeated swings between losses and profits make future earnings power less predictable and weaken confidence in consistent returns on the company’s medical network. This volatility can constrain reinvestment planning and makes operating performance more dependent on execution in each reporting period.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash generation
Recurring positive operating cash flow and strong free cash flow provide internal funding for clinical expansion, facility investment, and shareholder returns. The 2025 improvement in free cash flow also indicates better cash conversion, strengthening financial resilience over the next several quarters.
Read all positive factors

C-MER Eye Care Holdings Limited (3309) vs. iShares MSCI Hong Kong ETF (EWH)

C-MER Eye Care Holdings Limited Business Overview & Revenue Model

Company Description
C-MER Medical Holdings Limited specializes in offering both medical treatments and therapeutic services for a variety of eye conditions. Its business activities are segmented into two primary areas: the delivery of ophthalmological services and th...
How the Company Makes Money
C-MER primarily makes money by charging patients (and, where applicable, third-party payors) for clinical eye-care services delivered through its own medical network. Key revenue streams typically include: (1) outpatient services such as specialis...

C-MER Eye Care Holdings Limited Financial Statement Overview

Summary
Strong cash generation (positive operating cash flow every year and strong free cash flow in 2022–2025) and a generally stable, moderately levered balance sheet support the score. The main offset is earnings volatility, with losses in 2022 and 2024 despite improved profitability in 2025.
Income Statement
73
Positive
Balance Sheet
78
Positive
Cash Flow
84
Very Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.03B1.95B1.91B1.92B1.73B1.11B
Gross Profit633.13M603.67M527.62M618.96M365.34M309.44M
EBITDA373.27M341.37M343.30M363.38M194.31M177.80M
Net Income100.44M100.37M-135.16M62.00M-21.88M21.86M
Balance Sheet
Total Assets2.86B2.73B2.72B2.75B2.90B1.96B
Cash, Cash Equivalents and Short-Term Investments563.37M465.96M467.25M557.42M698.51M442.36M
Total Debt433.61M426.78M437.79M362.99M452.49M471.69M
Total Liabilities868.58M796.01M830.24M755.35M903.45M618.63M
Stockholders Equity1.83B1.77B1.75B1.85B1.87B1.33B
Cash Flow
Free Cash Flow323.23M223.94M124.50M245.30M100.63M19.18M
Operating Cash Flow400.23M301.47M283.12M361.15M191.86M148.41M
Investing Cash Flow-45.70M-169.66M-174.72M-245.37M-210.65M-392.72M
Financing Cash Flow-196.81M-212.38M-194.92M-242.88M293.68M85.12M

C-MER Eye Care Holdings Limited Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.70
Price Trends
50DMA
0.82
Positive
100DMA
0.88
Negative
200DMA
1.10
Negative
Market Momentum
MACD
0.01
Negative
RSI
56.19
Neutral
STOCH
80.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3309, the sentiment is Neutral. The current price of 1.7 is above the 20-day moving average (MA) of 0.81, above the 50-day MA of 0.82, and above the 200-day MA of 1.10, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 56.19 is Neutral, neither overbought nor oversold. The STOCH value of 80.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3309.

C-MER Eye Care Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
HK$1.66B8.346.97%10.27%3.85%-1.23%
71
Outperform
HK$581.85M5.276.35%10.92%-0.27%29.73%
68
Neutral
HK$1.47B4.1617.86%2.16%1.25%12.60%
67
Neutral
HK$1.05B10.105.57%2.29%4.75%―
66
Neutral
HK$703.50M285.710.20%2.00%20.54%-96.74%
52
Neutral
HK$1.10B78.100.48%1.10%-3.26%―
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:3309
C-MER Eye Care Holdings Limited
0.85
-0.91
-51.81%
HK:1526
Rici Healthcare Holdings Ltd.
0.93
-0.07
-7.22%
HK:1846
EuroEyes International Eye Clinic Limited
2.20
-1.09
-33.17%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.36
<0.01
0.43%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
1.74
-0.03
-1.97%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.11
-40.07%

C-MER Eye Care Holdings Limited Corporate Events

C-MER Medical Posts Higher Revenue but Softer Adjusted Profit in First Half of 2026
Aug 25, 2026
C-MER Medical Holdings Limited reported unaudited interim results for the six months ended 30 June 2026, showing revenue of HK$1,024.4 million, up 8.5% year on year. Gross profit rose 10.0% to HK$323.4 million and gross margin improved slightly to...
C-MER Completes Strategic Investment in CHIGENOVO and Secures Exclusive Rights to ZVS101e
Aug 10, 2026
C-MER Medical Holdings Limited has completed its previously announced investment transactions in CHIGENOVO Co., Ltd., a move that secures a strategic minority stake in the medical company. Through its subsidiary HK (International) Eye Care, C-MER ...
C-MER Medical Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 7, 2026
C-MER Medical Holdings Limited has scheduled a board meeting for 25 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider whether to recommend an interim dividend and handle other...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 06, 2026